Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update

Rhea-AI Summary

Halozyme (NASDAQ: HALO) will host an investor conference call on Wednesday, January 28, 2026 at 5:30 AM PT / 8:30 AM ET. Management led by Dr. Helen Torley, President and CEO, and Nicole LaBrosse, CFO, will provide preliminary unaudited full-year 2025 revenue results, updated 2026–2028 financial guidance, and a business update. The call requires pre-registration and will be webcast live via the Investors section of Halozyme.com, with presentation materials available 15 minutes before the call and a recording posted after the call.

News Market Reaction

+1.82%

1 alert

+1.82% News Effect

On the day this news was published, HALO gained 1.82%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, Jan. 20, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday, January 28, 2026, at 5:30 am PT / 8:30 am ET.

On the call, Dr. Helen Torley, President and Chief Executive Officer, and Nicole LaBrosse, Chief Financial Officer, will provide preliminary unaudited full year 2025 revenue results, updated 2026-2028 financial guidance and a business update.

Pre-registration of the live call can be accessed via link here: https://registrations.events/direct/Q4I1205969. The call will also be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast and presentation materials, which will be available 15 minutes before the call, please visit Halozyme.com.

About Halozyme

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE^® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE^® has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, and Merus N.V.

Halozyme is also developing partner products with Hypercon™ to expand the breadth of its drug delivery technology portfolio. Hypercon™ is an innovative microparticle technology that is expected to set a new standard in hyper concentration of drugs and biologics that can reduce the injection volume for the same dosage and expands opportunities for at-home and health care provider administration. The addition of Hypercon™ enhances our ability to transform the patient treatment experience by enabling the creation and delivery of highly concentrated biologics, substantially broadening the scope of therapeutics that can be delivered subcutaneously. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Johnson & Johnson, Eli Lilly, and argenx.

Halozyme also develops, manufactures, and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability, and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex^® and XYOSTED^®, partnered commercial products, and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.

Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility.

For more information, visit www.halozyme.com and connect with us on LinkedIn.

Contacts

Tram Bui
Halozyme
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com

Sydney Charlton
Teneo
917-972-8407
sydney.charlton@teneo.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-business-update-302665875.html

SOURCE Halozyme Therapeutics, Inc.

FAQ

When is Halozyme's investor call and how can I join (HALO)?

The call is on January 28, 2026 at 5:30 AM PT / 8:30 AM ET; join via pre-registration link or the Investors section at Halozyme.com for the live webcast.

What will Halozyme (HALO) announce on the January 28, 2026 call?

Management will provide preliminary unaudited full-year 2025 revenue results, updated 2026–2028 financial guidance, and a business update.

Who will present on Halozyme's (HALO) January 28, 2026 investor call?

Dr. Helen Torley, President and CEO, and Nicole LaBrosse, Chief Financial Officer, will lead the presentation.

Will Halozyme (HALO) provide presentation materials and a recording of the call?

Yes. Presentation materials will be available 15 minutes before the call and a recording will be posted after the call on Halozyme.com.

Are the revenue figures on the Halozyme (HALO) call audited?

The company will present preliminary unaudited full-year 2025 revenue results during the call.